Welcome to our dedicated page for Crescent Biopharma news (Ticker: CBIO), a resource for investors and traders seeking the latest updates and insights on Crescent Biopharma stock.
Crescent Biopharma reports news about its clinical-stage oncology pipeline, including CR-001, a PD-1 x VEGF bispecific antibody, and antibody-drug conjugate programs such as CR-002 and CR-003. Company updates commonly cover clinical trial activity in solid tumors, pipeline combinations, collaboration activity, financial results, and business highlights.
Recurring corporate announcements also include investor conference presentations and equity inducement awards under the company’s employment inducement incentive plan. These updates reflect Crescent’s status as a Nasdaq-listed biotechnology issuer focused on cancer therapeutics.
Crescent Biopharma (Nasdaq: CBIO) announced inducement option awards totaling 45,675 shares to two non-executive employees, approved March 5, 2026 under its 2025 Employment Inducement Incentive Award Plan. The options carry a 10-year term and an exercise price of $11.33 (Nasdaq close on March 5, 2026).
Vesting: 25% vests on the first anniversary of each employee’s start date, then 1/48th monthly thereafter, subject to continuous service and the plan and option agreement terms; grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
Crescent Biopharma (Nasdaq: CBIO) reported Q4 and full‑year 2025 results and business updates on Feb 26, 2026, highlighting a strategic partnership with Kelun‑Biotech, IND clearance and patient dosing for CR‑001, a global ASCEND Phase 1/2 trial, and a completed $185 million private placement that supports operations into 2028.
Crescent Biopharma (Nasdaq: CBIO) will present at two investor conferences in March 2026: TD Cowen on March 2 at 3:50 p.m. ET in Boston and Leerink Partners on March 11 at 8:40 a.m. ET in Miami.
According to Crescent Biopharma, each presentation will be webcast live and replays will be available via the Investors section of the company's website for 90 days.
Crescent Biopharma (Nasdaq: CBIO) announced inducement option awards totaling 24,600 shares to two non-executive employees approved February 17, 2026. The options have a 10-year term and an exercise price of $9.33, the February 17, 2026 closing price.
Vesting: 1/4 after one year from each employee's start date, then 1/48 monthly thereafter, subject to continuous service and plan terms.
Crescent Biopharma (Nasdaq: CBIO) announced dosing of the first patient in the global ASCEND Phase 1/2 trial of CR-001, a PD-1 x VEGF bispecific antibody, for advanced solid tumors on Feb 18, 2026.
ASCEND may enroll up to 290 patients across the US, Europe and Asia Pacific; the company expects proof-of-concept data in Q1 2027 and said ASCEND is the first of four portfolio trials planned to start in 2026.
Crescent Biopharma (Nasdaq: CBIO) management will present in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York on Thursday, February 12, 2026 at 11:30 a.m. ET. A live webcast will be available in the Investors section and a replay will be accessible for 90 days.
Crescent Biopharma (Nasdaq: CBIO) announced inducement equity option awards approved January 29, 2026, granting an aggregate of 117,339 options to five non-executive employees under the 2025 Employment Inducement Incentive Award Plan.
Options have a 10-year term, exercise price of $10.15, and standard four-year vesting with monthly vesting thereafter.
Crescent Biopharma (Nasdaq: CBIO) announced IND clearances for two oncology candidates: CR-001 (PD-1 x VEGF bispecific) cleared by the U.S. FDA and CR-003 (ITGB6-targeted ADC/SKB105) approved by China NMPA CDE via partner Kelun-Biotech. Crescent plans a global Phase 1/2 ASCEND trial for CR-001 in first-line and previously treated solid tumor patients, targeting enrollment of up to 290 participants and on track to start in Q1 2026. Proof-of-concept data from ASCEND is anticipated in Q1 2027. Crescent expects four clinical trials across its portfolio to initiate in 2026. The strategic collaboration with Kelun-Biotech defines ex-China and Greater China commercialization rights for the two programs.
Crescent Biopharma (Nasdaq: CBIO) announced inducement option awards to three non-executive employees under its 2025 Employment Inducement Incentive Award Plan.
The Board approved an aggregate of 129,626 options on December 13, 2025, and the options were granted on December 15, 2025. Each option has a 10-year term and an exercise price of $13.21, equal to the Nasdaq closing price on December 15, 2025. Vesting is 25% after the first anniversary of each employee’s start date, then monthly at 1/48th thereafter, subject to continuous service and the Inducement Plan terms.
Crescent Biopharma (Nasdaq: CBIO) announced an exclusive strategic partnership with Kelun-Biotech and a $185 million private placement expected to close on or about December 8, 2025. The financing of 13,795,685 ordinary shares at $13.41 per share (and pre-funded warrants) is expected to provide cash runway into 2028. The collaboration grants Kelun rights to CR-001 in Greater China and grants Crescent rights to SKB105 (CR-003) outside Greater China.
Pipeline milestones: global Phase 1/2 start for CR-001 in Q1 2026 with proof-of-concept data in Q1 2027; CR-003 (SKB105) Phase 1/2 in Q1 2026 with PoC in Q1 2027; CR-002 IND planned mid-2026 with PoC in H2 2027; initial ADC combination data expected by year-end 2027.